Following the release of favorable clinical-trial findings, Actinium Pharmaceuticals Inc. (NYSE: ATNM) shares increased 8.22% to trade at $10.53 at the time of the most recent check.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
What outcomes has ATNM disclosed?
Positive top-line findings from the pivotal Phase 3 study for its flagship product candidate, Iomab-B, were released by Actinium (ATNM) today. Patients 55 years of age or older with active illness participated in the SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) experiment (relapsed or refractory AML).
- In the SIERRA trial, a randomized, multicenter, controlled research, Iomab-B was compared to a control arm that permitted all currently available forms of traditional therapy with the goal of transplanting these patients.
- The SIERRA trial’s primary goal, durable complete remission, or dCR, was achieved in the Iomab-B arm compared to the standard treatment arm at 6 months after the first remission following a BMT, achieving statistical significance of p0.0001.
- For patients who require new therapeutic alternatives, ATNM’s important SIERRA study, which was randomized, controlled, and multi-center, has produced these findings.
- With Iomab-B, Actinium hopes to enhance patient outcomes and expand access to BMT; these topline data, given their statistical significance, point us in that direction.
- In order to get the US Food and Drug Administration (FDA) to approve Iomab-B, ATNM promised to keep working on the Biologics License Application (BLA).
How did ATNM achieve top-tier results?
This is a critical turning point in the life of Actinium (ATNM) and a testament to the caliber of its team that performed a ground-breaking investigation in a patient group that is generally thought to be untreatable. Despite ongoing staffing and resource shortages, their dedication and tenacity have paid off in a clinically significant way. The freshly bolstered team is working to carry out ATNM’s aim to use Iomab-B to revolutionize bone marrow conditioning, first in r/r AML and subsequently by expanding on its strong historical clinical performance in a number of hematological conditions. By year’s end, ATNM will provide further clinical information from the SIERRA study.
